Agenus

AGEN

Market cap $124M

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanced CTLA-4 antibody and balstilimab (BAL), a PD-1 inhibitor, combination demonstrating durable survival across multiple cancer types in late-stage patients who have limited treatment options. The results, featured in an oral session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germa.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ESMO2025--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at 4:00 p.m. ET. The webcast will feature updates from leading experts on recent clinical progress and expanding international access for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL). The session will be moderated by Garo Armen, PhD, Founder, Chairman, and CEO, and conclude with a live Q&A. Fea.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) under France's compassionate access (Accès compassionnel, or AAC) framework. The French National Agency of Medicines and Health Products Safety's (ANSM) listings for botensilimab and balstilimab are li.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Dr. Richard Goldberg, Chief Development Officer, and Dr. Robin Taylor, Chief Commercial Officer, will participate in a fireside chat on Tuesday, September 9, 2025, to provide strategic insights on Agenus'.

Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET which introduces a new virtual format to provide an engaging experience for attendees, along with an updated participation link. Stakeholder Webcast Participation Details NEW Audience Webcast Link | https://riverside.fm/studio/agenus-presentation Pre-registration is not required. The program will c.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ColorectalCancer--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnersh.

Agenus (AGEN) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $2.52 per share a year ago.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a next-generation, multifunctional, Fc enhanced, CTLA-4 antibody and BAL is a proprietary PD-1 antibody; t.

QS, CVEO, and AGEN show strong earnings acceleration this month - often a signal of stock price momentum ahead.